查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587809

白細胞介素抑制劑市場規模、佔有率、趨勢分析報告：按類型、給藥途徑、應用、最終用途、地區和細分市場預測，2025-2030 年

Interleukin Inhibitors Market Size, Share & Trends Analysis Report By Type, By Route Of Administration (SC, IV), By Application (RA, Psoriasis, IBD, Asthma), By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

白細胞介素抑制劑市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球白細胞介素抑制劑市場規模將達到722億美元，2025年至2030年複合年成長率為17.3%。

這背後是計劃推出的強大後期管線藥物。

該市場的治療情勢競爭日益激烈，目前正在透過頭對頭試驗對藥物進行比較，以確定其在安全性、有效性和耐受性方面的優越性。例如，UCB的bimekizumab目前正在針對Humira（研究名稱：BE SURE）、 Stelara （BE VIVID）和Cosentyx（BE RADIANT）進行三項針對斑塊型乾癬的臨床試驗。

此外，增加對各種臨床試驗的投資以及製藥公司和研究機構開發新分子的策略聯盟是促進白細胞介素抑制劑市場成長的主要因素之一。例如，基因泰克（F. Hoffmann-La Roche）正在與馬薩諸塞州總醫院合作開發Actemra（托珠單抗），一種治療鉅細胞動脈炎的藥物。

消費者對各種自體免疫疾病及其治療方案的認知不斷提高預計將推動需求。例如，愛爾蘭關節炎協會發起了一場類風濕性關節炎宣傳活動，教育大眾了解不同的治療方案和早期診斷的價值。歐洲克隆氏症症和潰瘍性大腸炎協會聯合會也在努力提高人們對發炎性腸道疾病(IBD) 患者的認知。

白細胞介素抑制劑市場報告亮點

  • 從應用來看，乾癬領域領先市場，到2024年將佔37.0%的佔有率。
  • 到2024年，IL-23抑制劑將憑藉其在治療乾癬和IBD等自體免疫疾病的有效性，以27.5%的銷售佔有率引領市場。
  • 按類型分類，IL-17 抑制劑在預測期內的複合年成長率預計將達到 16.1%。
  • 由於醫療基礎設施的改善和可支配收入的增加，預計亞太地區在預測期內將出現最快的成長。
  • 儘管 IL 抑制劑價格昂貴，但有利的報銷政策可能會使它們變得負擔得起並提高市場滲透率。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章白細胞介素介素抑制劑市場變數、趨勢、範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章白細胞介素抑制劑市場：按類型分類的業務分析

  • 2024 年和 2030 年按類型分類的市場佔有率
  • 類型細分儀表板
  • 2018-2030 年按類型分類的市場規模、預測與趨勢分析
  • IL-1抑制劑
  • IL-2抑制劑
  • IL-5抑制劑
  • IL-6抑制劑
  • IL-17抑制劑
  • IL-23抑制劑
  • 其他

第5章白細胞介素抑制劑市場：給藥途徑的業務分析

  • 2024 年及 2030市場佔有率給藥途徑途徑
  • 途徑細分儀表板
  • 2018-2030 年按管理途徑的市場規模、預測與趨勢分析
  • 皮下注射（SC）
  • 靜脈注射 (IV)

第6章白細胞介素抑制劑市場：應用業務分析

  • 2024年及2030年應用市場佔有率
  • 使用細分儀表板
  • 2018-2030 年按應用分類的市場規模、預測與趨勢分析
  • 類風濕性關節炎
  • 乾癬
  • 發炎性腸道疾病（IBD）
  • 氣喘
  • 其他

第7章白細胞介素抑制劑市場：最終用途業務分析

  • 2024 年及 2030 年最終用途市場佔有率
  • 最終用途細分儀表板
  • 2018-2030 年按最終用途分類的市場規模、預測與趨勢分析
  • 醫院
  • 專科診所
  • 其他

第8章白細胞介素抑制劑市場：按類型、給藥途徑、應用和最終用途的區域估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 按國家/地區分類，2018-2030
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區分類，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 按國家/地區分類，2018-2030
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類，2018-2030
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 按國家/地區分類，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 參與者概覽
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • Novartis AG
    • AbbVie Inc.
    • Eli Lilly and Company
    • Regeneron Pharmaceuticals Inc.
    • Johnson &Johnson Services, Inc.
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca
    • Bausch Health Companies Inc.
    • GlaxoSmithKline plc
    • Teva Pharmaceutical Industries Ltd
Product Code: GVR-3-68038-172-6

Interleukin Inhibitors Market Growth & Trends:

The global interleukin inhibitors market size is expected to reach USD 72.2 billion by 2030, registering a CAGR of 17.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. This can be attributed to a strong pipeline with upcoming launches of late-stage pipeline drugs.

The therapeutic landscape in this market is becoming increasingly competitive, as drugs are compared in head-to-head trials to determine superiority in terms of safety, efficacy, and tolerance. For instance, UCB's bimekizumab is currently under investigation in three such trials against Humira (trial name: BE SURE), Stelara (BE VIVID), and Cosentyx (BE RADIANT)-indicated for plaque psoriasis.

Furthermore, increasing investments on various clinical trials and strategic alliances between pharmaceutical companies and research organizations for development of novel molecules are few major contributors to interleukin inhibitors market growth. For instance, Genentech (F. Hoffmann-La Roche Ltd.) has collaborated with Massachusetts General Hospital for developing Actemra (tocilizumab) for the treatment of giant cell arteritis.

Rise in consumer awareness about various autoimmune diseases and their treatment options is anticipated to impel demand. For instance, Arthritis Ireland launched an awareness campaign for rheumatoid arthritis, educating the public about different treatment options and significance of early diagnosis. In addition, the European Federation of Crohn's & Ulcerative Colitis Association offers various initiatives to create awareness among patients suffering from Inflammatory Bowel Disease (IBD).

Interleukin Inhibitors Market Report Highlights:

  • By application, the psoriatic segment leading the market and accounted for a share of 37.0% in 2024
  • In 2024, IL-23 inhibitors led the market with a revenue share of 27.5%, due to their efficacy in treating autoimmune diseases, such as psoriasis and IBD.
  • By type, IL-17 inhibitors are expected to witness a significant CAGR of 16.1% over the forecast period.
  • Asia Pacific is expected to exhibit the fastest regional growth over the forecast period, fueled by enhanced healthcare infrastructure and growing disposable incomes.
  • Despite the high price of IL-inhibitors, favorable reimbursement policies are likely to provide affordability and support market penetration.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Route of Administration
    • 1.2.3. Application
    • 1.2.4. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Interleukin Inhibitors Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Interleukin Inhibitors Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. IL-1 Inhibitors
    • 4.4.1. IL-1 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.5. IL-2 Inhibitors
    • 4.5.1. IL-2 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.6. IL-5 Inhibitors
    • 4.6.1. IL-5 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.7. IL-6 Inhibitors
    • 4.7.1. IL-6 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.8. IL-17 Inhibitors
    • 4.8.1. IL-17 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.9. IL-23 Inhibitors
    • 4.9.1. IL-23 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Interleukin Inhibitors Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2024 & 2030
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Subcutaneous (SC)
    • 5.4.1. Subcutaneous (SC) Market, 2018 - 2030 (USD Million)
  • 5.5. Intravenous (IV)
    • 5.5.1. Intravenous (IV) Market, 2018 - 2030 (USD Million)

Chapter 6. Interleukin Inhibitors Market: Application Business Analysis

  • 6.1. Application Market Share, 2024 & 2030
  • 6.2. Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Rheumatoid Arthritis
    • 6.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
  • 6.5. Psoriasis
    • 6.5.1. Psoriasis Market, 2018 - 2030 (USD Million)
  • 6.6. Inflammatory Bowel Disease (IBD)
    • 6.6.1. Inflammatory Bowel Disease (IBD) Market, 2018 - 2030 (USD Million)
  • 6.7. Asthma
    • 6.7.1. Asthma Market, 2018 - 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Interleukin Inhibitors Market: End Use Business Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. End Use Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Hospitals
    • 7.4.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 7.5. Specialty Clinics
    • 7.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Interleukin Inhibitors Market: Regional Estimates & Trend Analysis by Type, Route of Administration, Application, and End Use

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Novartis AG
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. AbbVie Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Eli Lilly and Company
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Regeneron Pharmaceuticals Inc.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Johnson & Johnson Services, Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. F. Hoffmann-La Roche Ltd
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. AstraZeneca
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Bausch Health Companies Inc.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. GlaxoSmithKline plc
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Teva Pharmaceutical Industries Ltd
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global interleukin inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global interleukin inhibitors market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Global interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 Global interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 North America interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 8 North America interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
  • Table 9 North America interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 North America interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 11 North America interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 U.S. interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 13 U.S. interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 15 U.S. interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Canada interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 17 Canada interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Canada interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 19 Canada interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Mexico interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 21 Mexico interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 Mexico interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 23 Mexico interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Europe interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
  • Table 25 Europe interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 26 Europe interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 Europe interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 28 Europe interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29 UK interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 30 UK interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 UK interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 32 UK interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 Germany interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 34 Germany interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 Germany interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 36 Germany interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 France interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 38 France interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 France interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 40 France interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Italy interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 42 Italy interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Italy interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 44 Italy interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Denmark interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 46 Denmark interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Denmark interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 48 Denmark interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Spain interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 50 Spain interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Spain interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 52 Spain interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 Sweden interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 54 Sweden interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 Sweden interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 56 Sweden interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 Norway interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 58 Norway interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59 Norway interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 60 Norway interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 Japan interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 67 Japan interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 68 Japan interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 69 Japan interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 China interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 71 China interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 China interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 73 China interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 India interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 75 India interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 India interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 77 India interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 Australia interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 79 Australia interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 Australia interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 81 Australia interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 South Korea interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 83 South Korea interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 84 South Korea interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Korea interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Thailand interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 87 Thailand interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 88 Thailand interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 89 Thailand interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 Latin America interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
  • Table 91 Latin America interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 92 Latin America interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 93 Latin America interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 94 Latin America interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 95 Brazil interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 96 Brazil interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 97 Brazil interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 98 Brazil interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99 Argentina interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 100 Argentina interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 101 Argentina interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 102 Argentina interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108 South Africa interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 109 South Africa interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 110 South Africa interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 111 South Africa interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116 UAE interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 117 UAE interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 118 UAE interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 119 UAE interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 120 Kuwait interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 121 Kuwait interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 122 Kuwait interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 123 Kuwait interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Interleukin inhibitors market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook (USD Million)
  • Fig. 10 Segment outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Interleukin inhibitors market dynamics
  • Fig. 13 Interleukin inhibitors market: Porter's five forces analysis
  • Fig. 14 Interleukin inhibitors market: PESTLE analysis
  • Fig. 15 Interleukin inhibitors market: Type segment dashboard
  • Fig. 16 Interleukin inhibitors market: Type market share analysis, 2024 & 2030
  • Fig. 17 IL-1 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 18 IL-2 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 19 IL-5 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 20 IL-6 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 21 IL-17 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 22 IL-23 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Interleukin inhibitors market: Route of administration segment dashboard
  • Fig. 25 Interleukin inhibitors market: Route of administration market share analysis, 2024 & 2030
  • Fig. 26 Subcutaneous (SC) market, 2018 - 2030 (USD Million)
  • Fig. 27 Intravenous (IV) market, 2018 - 2030 (USD Million)
  • Fig. 28 Interleukin inhibitors market: Application segment dashboard
  • Fig. 29 Interleukin inhibitors market: Application market share analysis, 2024 & 2030
  • Fig. 30 Rheumatoid arthritis market, 2018 - 2030 (USD Million)
  • Fig. 31 Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 32 Inflammatory bowel disease (IBD) market, 2018 - 2030 (USD Million)
  • Fig. 33 Asthma market, 2018 - 2030 (USD Million)
  • Fig. 34 Others market, 2018 - 2030 (USD Million)
  • Fig. 35 Interleukin inhibitors market: End use segment dashboard
  • Fig. 36 Interleukin inhibitors market: End use market share analysis, 2024 & 2030
  • Fig. 37 Hospitals market, 2018 - 2030 (USD Million)
  • Fig. 38 Specialty clinics market, 2018 - 2030 (USD Million)
  • Fig. 39 Others market, 2018 - 2030 (USD Million)
  • Fig. 40 Interleukin inhibitors market revenue, by region
  • Fig. 41 Regional marketplace: Key takeaways
  • Fig. 42 Regional marketplace: Key takeaways
  • Fig. 43 North America interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. country dynamics
  • Fig. 45 U.S. interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 46 Canada country dynamics
  • Fig. 47 Canada interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 48 Mexico country dynamics
  • Fig. 49 Mexico interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 50 Europe interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 51 UK country dynamics
  • Fig. 52 UK interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 53 Germany country dynamics
  • Fig. 54 Germany interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 55 France country dynamics
  • Fig. 56 France interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 57 Italy country dynamics
  • Fig. 58 Italy interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 59 Spain country dynamics
  • Fig. 60 Spain interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 61 Norway country dynamics
  • Fig. 62 Norway interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 63 Sweden country dynamics
  • Fig. 64 Sweden interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 65 Denmark country dynamics
  • Fig. 66 Denmark interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 68 Japan country dynamics
  • Fig. 69 Japan interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 70 China country dynamics
  • Fig. 71 China interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 72 India country dynamics
  • Fig. 73 India interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 74 Australia country dynamics
  • Fig. 75 Australia interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 76 South Korea country dynamics
  • Fig. 77 South Korea interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 78 Thailand country dynamics
  • Fig. 79 Thailand interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 81 Brazil country dynamics
  • Fig. 82 Brazil interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 83 Argentina country dynamics
  • Fig. 84 Argentina interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 85 MEA interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 86 South Africa country dynamics
  • Fig. 87 South Africa interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia country dynamics
  • Fig. 89 Saudi Arabia interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 90 UAE country dynamics
  • Fig. 91 UAE interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait country dynamics
  • Fig. 93 Kuwait interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 94 Company categorization
  • Fig. 95 Company market position analysis
  • Fig. 96 Strategic framework